Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 30, 2026
TickeronGET DAILY SIGNALS
Quanterix Corporation (QTRX) Stock Drops -22.9% in 30 Days: Factors Behind the Move

Quanterix Corporation (QTRX) Stock Drops -22.9% in 30 Days: Factors Behind the Move

Key Takeaways

  • Quanterix Corporation (QTRX) declined roughly 22.9% over the last 30 days, falling from a September 30 close of $3.71 to about $2.86.
  • The drop extends a broader downtrend, with the stock down approximately 18.8% over the last quarter.
  • Persistent weakness in academic and pharmaceutical end-market demand, combined with commercial execution challenges flagged earlier in the year, has weighed on sentiment.
  • Quanterix reduced its full-year 2026 revenue guidance in August, and the analyst consensus remains a Hold with an average price target near $3.17.
  • The company is scheduled to report third-quarter 2026 financial results on November 9, 2026, a key near-term catalyst for the stock.

Company Overview and Market Position

Quanterix Corporation, headquartered in Billerica, Massachusetts, is a life sciences company focused on precision biomarker science. Its proprietary Simoa technology enables ultra-sensitive detection and quantification of protein biomarkers in blood and other fluids at concentrations far below traditional immunoassay limits. Through its acquisition of Akoya Biosciences, the company also offers spatial biology solutions that measure protein expression in tissue at single-cell resolution, along with Accelerator Laboratory services that support researchers from discovery through diagnostic development. Quanterix primarily serves the neurology, oncology, immunology, and inflammation markets, selling instruments, assays, reagents, and services to academic institutions, pharmaceutical and biotechnology companies, and contract research organizations. I follow the stock closely because of its exposure to high-growth areas such as blood-based biomarker testing for neurological disease and its expansion into spatial biology. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Price Performance Over the Last 30 Days and Quarter

Over the last 30 days, QTRX shares have fallen approximately 22.9%, declining from a closing price of $3.71 on September 30 to around $2.86. The decline was not a straight line: the stock briefly traded above $3.90 in early October before a steady slide through the second half of the month brought it below $2.80 at times.

The last quarter tells a similar, more extended story. From a closing price of $3.52 on July 30, the stock has dropped about 18.8%. The quarterly period captured the sharpest single-session move, when shares fell sharply in mid-August following second-quarter results, before a partial recovery in September and renewed selling in October. The overall trend over both timeframes has been lower, reflecting sustained caution around near-term growth. From what I see, this performance highlights ongoing investor caution.

Drivers of the Recent 30-Day Decline

The 30-day decline has been driven primarily by lingering concerns over demand and execution rather than a single new negative event. In early October, Quanterix and its partner Innovita announced National Medical Products Administration (NMPA) approvals in China for Simoa instruments and neurology biomarker assays, and the company highlighted progress in spatial biology content. These were constructive developments, yet they were not enough to offset the broader cautious tone.

Market sentiment has remained restrained by the weaker-than-expected second quarter reported in August, when revenue came in below guidance and the company lowered its full-year outlook. Analysts have kept a Hold consensus on the stock, with an average price target near $3.17, reflecting limited near-term upside expectations. The combination of soft end-market demand, questions about commercial execution, and positioning ahead of the upcoming third-quarter earnings report contributed to the stock's pullback during the period. I’m watching this closely as earnings approach.

Quarterly Performance and the August Earnings Impact

The dominant event shaping Quanterix's performance over the last quarter was its second-quarter 2026 earnings report in August. The company reported revenue of about $32.9 million, roughly 9% below the guidance it had provided earlier, and reduced its full-year 2026 revenue outlook to a range of $142 million to $148 million from a prior range of $169 million to $174 million. Management cited broad-based market softness and commercial execution challenges, and also pushed its cash-flow breakeven target to 2027 from the second half of 2026. The report included a sizable non-cash goodwill impairment charge.

The stock fell sharply following that announcement and has since struggled to rebuild momentum. A September recovery gave way to renewed selling in October, as investors weighed slower growth in academic and pharmaceutical spending against the company's longer-term diagnostics and spatial biology initiatives. The broader narrative remains one of a company repositioning its commercial organization while navigating a challenging funding environment. One thing that stands out is how these execution issues have persisted.

What to Watch Ahead of the November Earnings Report

The most immediate catalyst for QTRX is its third-quarter 2026 earnings report, scheduled for November 9, 2026. Investors will focus on revenue performance relative to expectations, updated full-year guidance, gross margin trends, and commentary on cash usage, given the company's revised breakeven timeline. Demand conditions in academic and government-funded research, as well as pharmaceutical spending, remain central to the outlook, since these segments drove much of the recent softness.

Additional factors to monitor include the commercial ramp of the Simoa and spatial biology businesses, progress on diagnostics initiatives such as blood-based neurology testing, and any further regulatory or partnership developments in international markets. Analyst revisions to price targets and ratings will also be closely watched. These are informational considerations, not investment recommendations, and outcomes will depend on execution and broader market conditions. In my view, the upcoming report could clarify the path forward.

Using AI Tools in My Research Process

In reviewing market trends for stocks like this, I frequently turn to Tickeron’s AI Trading Bots to observe how algorithmic strategies are positioned across similar names. These tools provide a helpful lens on shifting sentiment and help me cross-check traditional analysis with data-driven signals without replacing my own judgment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: QTRX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


QTRX in downward trend: price dove below 50-day moving average on November 11, 2026

QTRX moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend. In 37 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QTRX as a result. In 78 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for QTRX turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 42 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

The 10-day moving average for QTRX crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +22.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTRX advanced for three days, in 209 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

QTRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 128 of 144 cases where QTRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.577) is normal, around the industry mean (4.142). P/E Ratio (-1.105) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.894) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. QTRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of protein diagnostic platform

Industry MedicalNursingServices

Industry
Pharmaceuticals Major
Address
900 Middlesex Turnpike
Phone
+1 617 301-9400
Employees
151
Web
https://www.quanterix.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.